Nanobodies from cows can treat COVID-19: Study

Small antibodies produced by cows can be sprayed through the nose and can be treated with a new line of treatment for the coronavirus caused by COVID-19.

Researchers at the Rosalind Franklin Institute in the United Kingdom say that nanoparticles: a small, simple antibody that can accurately target the SARS-CoV-2 virus. The study, published in the journal Nature Communication, found that short-chain molecules that can be produced in the laboratory significantly reduced COVID-19 symptoms when transmitted to infected animal models.

The nanoparticles, which are closely linked to the SARS-CoV-2 virus in cell culture, may be cheaper and easier to use than human antibodies derived from patients recovering from COVID-19, the researchers said. During the epidemic, human antibodies became a key treatment for serious COVID-19 cases, but they should usually be given injections at the hospital, he said.

“Nanobodies have many benefits against human antibodies,” says Professor Ray Owens, of the Rosalind Franklin Institute and lead author of research. “They are inexpensive to produce and can be delivered directly to the airways by a nebulizer or a nasal spray, so you can manage yourself at home instead of needing an injection,” Owens said.

This may have benefits for patients’ ease of use but it can be treated directly in the respiratory tract.

The team incorporated a portion of the SARS-CoV-2 spin protein into Fifi, which is part of the University of England’s Anti-Productivity Institute, to produce nanoparticles.

Spicy proteins are found outside the virus and are responsible for binding them to human cells. Although the needles did not infect Fifi, it stimulated the immune system to fight the virus by producing nanoparticles.

Then a small blood sample was taken from the cow and the researchers were able to clean four nanoparticles that could be linked to the SARS-CoV-2 virus. The nanobods are then combined into three chains to increase their resistance to the virus. These are produced in cells in the laboratory.

The team, which includes scientists from Liverpool Liverpool University, Oxford University and Public Health England, has identified three nano-canal chains, both the first SARS-CoV-2 virus and the alpha variant identified in Kent. , UK. The fourth nano-human chain was able to neutralize South Africa’s first pre-emptive distinction.

When administered by one of the Nanobor chains to Sano-Covi-2, the animals showed a significant reduction in weight loss seven days after the onset of the disease. The hammers treated with nanoparticles also had lower viral load in their lungs and airways seven days after untreated animals, the researchers said.

Professor James Naimism (, director of the Roslind Franklin Institute

Professor James Naimizit, director of the Roslind Franklin Institute, said: Although vaccines have been very successful, not everyone responds to them and immunizations can be reduced in individuals at different times.

“It is still important to find drugs that can cure the virus, especially since the whole world is not vaccinated at the same rate and there is still a risk of new mutants developing immunosuppressants,” he said. “Successful and proven nanobodies are easier to produce than antibodies and cannot be stored in cold storage facilities, so they can provide needed treatment around the world,” he added.


Leave a Comment